X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Multiply Labs Partners To Automate Cell Therapy Production

Content Team by Content Team
6th May 2022
in News
Multiply Labs Partners To Automate Cell Therapy Production

Multiply Labs is equipping itself with two additional pieces of industry-leading tech in its quest to automate manual elements of the cell therapy production process. The new kit arrives little over a year after the robotics company reported a cooperation aimed at developing a robotic manufacturing system for mass-producing cell treatments. Multiply Labs is expanding its workforce after recruiting Cytiva and the University of California, San Francisco (UCSF), according to the companies. Thermo Fisher Scientific and Charles River Laboratories are among the newcomers.

Cytiva, Thermo Fisher, and Charles River will help pave the path for automating bioreactors, incubators, and quality control screening, respectively, with Multiply handling robots and UCSF managing the cell production process itself.

According to co-founder and CEO of Multiply, Fred Parietti, the company’s ultimate goal is to streamline and automate the cell therapy manufacturing process. Similarly, the partnership hopes to demonstrate its progress at UCSF by the end of the year, he noted. Mechanical arms, fronted by cube-shaped modules, slide and rotate to move materials through production steps in the consortium’s manufacturing system.

The cluster, which would be managed by cloud-based software, would also allow sections of the process of production to run concurrently rather than sequentially, as is more prevalent today. The cluster itself is around nine feet tall and takes up only 150 square feet, as per Parietti, with a pattern of 2×5 cube modules on each side.

He said that because there are no humans within the cluster—only a pair of robotic arms—it works as its own clean room, preventing infection. The consortium is based on the realisation that they are far better off working together, according to Parietti, who added that if everyone attempted to reinvent the wheel, they’d still be here in ten years.

Cytiva is collaborating with Multiply Labs to streamline the operation of its Xuri bioreactors, with the goal of decreasing physical contact points by allowing robots to manage the process. Thermo Fisher is supplying Heracell VIOS incubators with the intention of automating the equipment’s operation with Multiply Labs’ guidance.

Meanwhile, Charles River is in charge of quality control. The businesses stated that automation of Charles River’s quality control test procedures could greatly expedite the manufacturing process, in addition to lowering the risk of human error.

Traditional manufacturing, which can require man-hours of handling of cells and consumables, isn’t cutting it for hundreds of developers pushing their cell and gene candidates through the clinic, according to Multiply Labs.

In cell therapy, there is a massive imbalance between demand and availability, Parietti explained. Manufacturing techniques for presently licenced cell therapies like CAR-Ts are already struggling to keep up, and with hundreds more clinical candidates in the pipeline, it is indeed evident that one needs the latest tech, as per Parietti. They simply believe that robot technology is more efficient and faster.

Previous Post

Amphista and BMS partner to develop protein degradation therapies

Next Post

FDA Regulates Use of J&J COVID Jab Due To Risk Of Thrombosis

Related Posts

DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Drug Development

Advanced Instruments All Set To Merge With Nova Biomedical

22nd March 2025
Drug Development

Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

21st March 2025
Clinical Trials

Oracle Wins the Asia Pacific Biopharma Excellence Awards

21st March 2025
Clinical Trials

Bio-Rad to Acquire Stilla Technologies by Q3 2025

28th February 2025
Next Post
Johnson & Johnsons's single-dose COVID-19 vaccine gets approval for emergency use in India

FDA Regulates Use of J&J COVID Jab Due To Risk Of Thrombosis

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In